Clinical trials: Allogeneic Stem-Cell Transplant
Hematologic Malignancy
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
The purpose of this research study is to examine the survival of patients undergoing partially matched hematopoietic stem cell transplant (HSCT) on a new type of treatment approach, which has been developed specifically for…
- Trial name
- NCT01341301
- Testing
- Total Body Irradiation, Donor Lymphocyte Infusion (DLI), Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Acute Myeloid Leukemia (AML)
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
The purpose of this study is to find out if azacitidine and venetoclax are an effective treatment approach to get rid of or lower measurable residual disease (MRD) in people with acute myeloid leukemia (AML) who have received…
- Trial name
- NCT06773208
- Testing
- Azacitidine (AZC), Venetoclax
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cytomegalovirus Infections
Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants
This study examines the immunologic and virologic effects of prophylactic CMV specific CTL in recipients of T cell depleted stem cell transplant (TCD SCT) at Duke University Medical Center (DUMC), by measuring levels of CMV DNA…
- Trial name
- NCT00673868
- Testing
- CMV Specific Cytotoxic T Lymphocytes
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Milton S. Hershey Medical Center
Hematologic Malignancy, Older Patients
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for older patients with hematologic malignancies
- Conditions
- Hematologic Malignancy, Older Patients, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT05084027
- Testing
- venetoclax combining with fludarabine and melphalan
- Where
- 8 sites in China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hematopoietic Stem Cell Transplantation
Fitness in Allogeneic Stem Cell Transplantation
Purpose: The primary hypothesis of this study is that the combination of interval exercise training (IET) as well as motivational accelerometry (MA) delivered both as a 5-12 week intervention that will improve cardiorespiratory…
- Trial name
- FAST (NCT02564458)
- Testing
- Interval Exercise Training/Motivational Accelerometry
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Graft vs Host Disease
Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients
Antifungal prophylaxis should be used in patients being treated with glucocorticoids for graft-versus-host disease (GVHD) following allogeneic hematopoietic stem-cell transplantation (HSCT).
- Trial name
- ITRAG (NCT01282879)
- Testing
- Itraconazole
- Where
- 9 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Samsung Medical Center
Aplastic Anemia
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
Patients have been diagnosed with severe Aplastic Anemia that have not responded to treatment with immunosuppressive therapy (drugs that suppress the immune system, for example Steroids).
- Trial name
- NCT00578903
- Testing
- Cytoxan, Campath, Total Body Irradiation (TBI)
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Baylor College of Medicine
Systemic Lupus Erythematosus
Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus
This trial is designed to evaluate the safety of treating systemic lupus erythematosus participants with cyclophosphamide and CAMPATH-1H followed by allogeneic stem cell transplant. There will be no randomization in this study.
- Trial name
- NCT00278590
- Testing
- Allogeneic Stem Cell Transplantation
- Where
- United States
- Sponsor
- Northwestern University
Chronic Effect of Ultraviolet Radiation on Photoaged Skin, Dermatologic Disorders
Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging
The purpose of this study is to determine whether a one-time injection of allogeneic mesenchymal bone marrow cells is safe and beneficial in the treatment of photodamage on the face.
- Trial name
- NCT01771679
- Testing
- Allogeneic Mesenchymal Bone Marrow Cells
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Stemedica Cell Technologies, Inc.
Neuroblastoma
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
Neuroblastoma (NB) is the most common extracranial solid tumor of embryonal origin in children. According to the International Neuroblastoma Risk Group (INRG) staging criteria and the International Neuroblastoma Staging System…
- Trial name
- NCT05303727
- Testing
- Anti Thymocyte Globulin, Fludarabine, Cyclophosphamide injection
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Corticosteroid Refractory Acute Graft vs Host Disease
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.
- Trial name
- REACH2 (NCT02913261)
- Testing
- Ruxolitinib (RUX), Best Available Therapy (BAT)
- Where
- 103 sites in Australia, Austria and 20 more
- Volunteers
- 310 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00907036
- Testing
- alemtuzumab, donor lymphocytes, cyclosporine
- Volunteers
- 49 people
- Sponsor
- Cancer Research UK
Myelofibrosis
Bone Marrow Transplant Chart Review for RIC
We will evaluate the records of 30 patients that have undergone allogeneic transplant, specifically looking at engraftment rate, relapse rate, disease free survival, overall survival, causes of death and other pertinent…
- Trial name
- NCT00723333
- Testing
- Reduced Intensity Conditioning (RIC) Allogenic Transplant
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
Multiple Myeloma
Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma
This study is a Phase I (non-randomized) study evaluating three dose-levels of Lenalidomide in patients after allogeneic stem cell transplantation, accomplished in two institutions (University Medical Center Hamburg-Eppendorf/…
- Trial name
- NCT00778752
- Testing
- Revlimid (Lenalidomide)
- Where
- 2 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
This clinical trial studies the side effects and best dose of giving fludarabine and total-body irradiation (TBI) together followed by a donor stem cell transplant and cyclosporine and mycophenolate mofetil in treating human…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00112593
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
Juvenile Myelomonocytic Leukemia
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia
This randomized phase II trial studies how well giving busulfan, cyclophosphamide, and melphalan or busulfan and fludarabine phosphate before donor hematopoietic cell transplant works in treating younger patients with juvenile…
- Trial name
- NCT01824693
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide
- Where
- 50 sites in United States, Australia and 2 more
- Volunteers
- 30 people
- Sponsor
- Children's Oncology Group
Leukemia
Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I
Effective treatment options for chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients with the T315I mutation are few.
- Trial name
- NCT02981784
- Testing
- Ponatinib (Iclusig®), allogeneic stem cell transplantation
- Where
- France
- Volunteers
- 184 people
- Sponsor
- Hospices Civils de Lyon
Aplastic Anaemia (AA), Allogeneic Haematopoietic Stem Cell Transplantation
Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
This study is a prospective, randomized, controlled, multicenter clinical trial. It plans to enroll 132 female SAA patients aged 14-50 years from multiple medical centers nationwide who are scheduled to undergo allo-HSCT.
- Conditions
- Aplastic Anaemia (AA), Allogeneic Haematopoietic Stem Cell Transplantation, Ovarian Insufficiency
- Trial name
- NCT07552506
- Testing
- Goserelin Depot
- Where
- 5 sites in China
- Volunteers
- 132 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Acute Graft Versus Host Disease
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
The study was an open-label, single-arm, Phase I/II multi-center study to investigate the PK, activity and safety of ruxolitinib added to the patient's immunosuppressive regimen in infants, children, and adolescents ages ≥28 days…
- Trial name
- NCT03491215
- Testing
- Ruxolitinib
- Where
- 19 sites in Belgium, Canada and 6 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation
Hematopoietic stem cell transplantation (HSCT) is one of the best, and sometimes the only, option for the treatment of leukemia.
- Trial name
- NCT01517347
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking University People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.